Ignite Creation Date:
2025-12-24 @ 2:12 PM
Ignite Modification Date:
2026-01-19 @ 5:52 PM
Study NCT ID:
NCT02115295
Status:
RECRUITING
Last Update Posted:
2025-11-06
First Post:
2014-04-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-05-19
Start Date Type:
ACTUAL
Primary Completion Date:
2030-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2014-04-14
First Submit QC Date:
None
Study First Post Date:
2014-04-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-05
Last Update Post Date:
2025-11-06
Last Update Post Date Type:
ESTIMATED